Welcome to our dedicated page for Harpoon Therapeutics news (Ticker: $HARP), a resource for investors and traders seeking the latest updates and insights on Harpoon Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Harpoon Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Harpoon Therapeutics's position in the market.
Rhea-AI Summary
Merck (MRK) acquires Harpoon Therapeutics, broadening its oncology pipeline with T-cell engagers like MK-6070 targeting DLL3. MK-6070 is in Phase 1/2 trials for small cell lung cancer (SCLC) and neuroendocrine tumors. Merck records a $650 million charge for the acquisition, impacting non-GAAP EPS by $0.26 per share for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Merck (MRK) to Acquire Harpoon Therapeutics (HARP) for $680 Million, Adding HPN328 to Its Oncology Pipeline
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
111.94%
Tags
-
Rhea-AI Summary
Harpoon Therapeutics, Inc. (Nasdaq: HARP) appoints James Bucher, J.D. as Chief Legal Officer and promotes Wendy Chang to Chief People Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
Rhea-AI Summary
Harpoon Therapeutics, Inc. (Nasdaq: HARP) announced the upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types at the ASCO-GU Symposium. HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon’s proprietary TriTAC® platform designed to recruit a patient’s own immune cells to kill tumor cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
-
Rhea-AI Summary
Harpoon Therapeutics, a clinical-stage immunotherapy company (Nasdaq: HARP), reported favorable data from the Phase 1 study of HPN217 in patients with RRMM at the 65th American Society of Hematology Annual Meeting. The RP2D of 12 mg demonstrated a 63% Overall Response Rate, with 53% achieving Very Good Partial Response or better. The data supports further clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
-
News
Rhea-AI Summary
Harpoon Therapeutics, Inc. (NASDAQ: HARP) reported positive interim results from Phase 1/2 trial of T cell engager HPN328 in patients with small cell lung cancer and other neuroendocrine tumor types at ESMO 2023. The company also completed a financing of up to $150 million, extended cash runway into 2026, and regained compliance with Nasdaq listing standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
Rhea-AI Summary
Harpoon Therapeutics (Nasdaq: HARP) announced the acceptance of abstract and upcoming oral presentation of the results from the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma. The presentation will take place at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition on December 11, 2023. The study focuses on a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) targeting B Cell Maturation Antigen (BCMA).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.18%
Tags
-
Rhea-AI Summary
Harpoon Therapeutics, Inc. has entered into a securities purchase agreement for a PIPE financing that is expected to result in upfront gross proceeds of approximately $100 million, with up to an additional approximately $50 million of gross proceeds upon cash exercise of warrants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.26%
Tags
-
Rhea-AI Summary
Harpoon Therapeutics announces updated interim data from Phase 1/2 clinical trial of HPN328 in small cell lung cancer and other neuroendocrine tumor types
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Harpoon Therapeutics to host webcast to review interim data from Phase 1/2 clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.99%
Tags
Harpoon Therapeutics, Inc.
NYSE:HARP
HARP Rankings
HARP Stock Data
492.35M
10.15M
0.35%
82.85%
2.52%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
US
South San Francisco
About HARP
harpoon therapeutics is a pre-clinical stage biotechnology company co-founded by patrick bauerle, a pioneer in t-cell engagement, and luke evnin (mpm capital) in 2015 to develop and commercialize a novel class of t cell recruiting antibodies engage a patient’s own immune cells to fight cancer and other diseases. the world-class team of protein engineers and immunologists at harpoon have built upon the successful development of the bispecific (“bite™ or bispecific t cell engager”) antibody blincyto® to create a next-generation company dedicated to the development of novel non-antibody biologic therapies with improved efficacy and broad applicability in the treatment of human cancers and other life-altering diseases of the immune system. harpoon’s tri-specific t-cell redirection platform -- tritac™ -- was designed to address the needs of cancer patients not being met by current checkpoint inhibitors, bi-specifics, car-t and other t-cell engaging approaches by improving activity against